Secondary plasma cell leukaemia treated with single agent venetoclax

Br J Haematol. 2020 Aug;190(4):e242-e245. doi: 10.1111/bjh.16858. Epub 2020 Jun 11.

Authors

Siobhan V Glavey¹, Lyndsey Flanagan², Rachel Bleach², Claire Kelly¹, John Quinn¹, Tríona Ní Chonghaile², Philip Murphy¹

Affiliations

¹ Department of Haematology, Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland.
² Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.

PMID: 32525557
DOI: 10.1111/bjh.16858

No abstract available

Keywords: BCL-2; leukaemia cytogenetics; leukaemia therapy; multiple myeloma; myeloma theraphy.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Chromosomes, Human, Pair 11 / genetics
Chromosomes, Human, Pair 11 / ultrastructure
Chromosomes, Human, Pair 14 / genetics
Chromosomes, Human, Pair 14 / ultrastructure
Combined Modality Therapy
Drug Resistance, Neoplasm
Female
Humans
Leukemia, Plasma Cell / blood
Leukemia, Plasma Cell / drug therapy*
Leukemia, Plasma Cell / genetics
Leukemia, Plasma Cell / therapy
Multiple Myeloma / drug therapy
Neoplasm Proteins / antagonists & inhibitors
Neoplasms, Second Primary / drug therapy*
Plasma Cells
Plasmapheresis
Progression-Free Survival
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
Sulfonamides / pharmacology
Sulfonamides / therapeutic use*
Translocation, Genetic

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Antineoplastic Agents, Immunological
Bridged Bicyclo Compounds, Heterocyclic
Neoplasm Proteins
Proto-Oncogene Proteins c-bcl-2
Sulfonamides
daratumumab
venetoclax

Grants and funding

AbbVie